Literature DB >> 25610731

The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy.

Jennifer A Westwood1, Phillip K Darcy2, Michael H Kershaw2.   

Abstract

This commentary provides the authors' perspective on the article "Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice", published in PLoS ONE. It also discusses the caveats of using subcutaneous tumors to model the treatment of human cancers versus orthotopic mouse models that more closely mimic human disease.

Entities:  

Keywords:  cancer; immunotherapy; mouse model; orthotopic; preclinical

Year:  2014        PMID： 25610731      PMCID： PMC4292559          DOI： 10.4161/21624011.2014.946361

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.

Authors:  Jennifer A Westwood; Nicole M Haynes; Janelle Sharkey; Nicole McLaughlin; Hollie J Pegram; Reto A Schwendener; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

2.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

3.  Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.

Authors:  Jennifer A Westwood; Phillip K Darcy; Preethi Mayura Guru; Janelle Sharkey; Hollie J Pegram; Sally M Amos; Mark J Smyth; Michael H Kershaw
Journal:  J Transl Med       Date:  2010-04-28       Impact factor: 5.531

Review 4.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 5.  Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.

Authors:  Bruce A Ruggeri; Faye Camp; Sheila Miknyoczki
Journal:  Biochem Pharmacol       Date:  2013-06-28       Impact factor: 5.858

6.  Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice.

Authors:  Jennifer A Westwood; Titaina C U Potdevin Hunnam; Hollie J Pegram; Rodney J Hicks; Phillip K Darcy; Michael H Kershaw
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 7.  Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.

Authors:  Christel Devaud; Liza B John; Jennifer A Westwood; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2013-08-22       Impact factor: 8.110

8.  Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models.

Authors:  Myriam N Bouchlaka; William J Murphy
Journal:  Oncoimmunology       Date:  2013-12-09       Impact factor: 8.110

Review 9.  Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.

Authors:  Michael H Kershaw; Christel Devaud; Liza B John; Jennifer A Westwood; Phillip K Darcy
Journal:  Oncoimmunology       Date:  2013-08-02       Impact factor: 8.110

10.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110
  10 in total
  4 in total

1.  Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.

Authors:  Nataša Obermajer; Julie Urban; Eva Wieckowski; Ravikumar Muthuswamy; Roshni Ravindranathan; David L Bartlett; Pawel Kalinski
Journal:  Nat Protoc       Date:  2018-01-18       Impact factor: 13.491

2.  Differences in predictions of ODE models of tumor growth: a cautionary example.

Authors:  Hope Murphy; Hana Jaafari; Hana M Dobrovolny
Journal:  BMC Cancer       Date:  2016-02-26       Impact factor: 4.430

Review 3.  Mouse Tumor Models for Advanced Cancer Immunotherapy.

Authors:  Daria S Chulpanova; Kristina V Kitaeva; Catrin S Rutland; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Int J Mol Sci       Date:  2020-06-09       Impact factor: 5.923

4.  Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.

Authors:  Vanessa Tran Chau; Winchygn Liu; Marine Gerbé de Thoré; Lydia Meziani; Michele Mondini; Mark J O'Connor; Eric Deutsch; Céline Clémenson
Journal:  Br J Cancer       Date:  2020-06-17       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.